While several preclinical studies in glioma models treated with oHSV M002 showed higher numbers of CD8+ cells relative to non-treated control tumors11,55, studies using alternative oHSV constructs showed no significant differences in numbers of CD8+ tumor infiltrating lymphocytes between treatment and control groups13. The gene discussed is CD8A; the disease is glioma.